Daily Archives: May 27, 2016

Hepatitis C and Numerous Disappearing Hepatic Nodules: No-dule C It, No-dule Don’t

Posted on May 27, 2016 by Matthew J. Klinge, Amir A. Borhani, Shahid M. Malik

Question: A 52-year-old Caucasian male with a past medical history of hypertension underwent evaluation for chronic, intermittent abdominal discomfort. He drank an average of 48 ounces of beer daily and had a remote history of intravenous drug use. He … Continue reading →

Posted in News | Comments Off on Hepatitis C and Numerous Disappearing Hepatic Nodules: No-dule C It, No-dule Don’t

Hepatitis C and Numerous Disappearing Hepatic Nodules: No-dule C It, No-dule Don’t

Posted on May 27, 2016 by Matthew J. Klinge, Amir A. Borhani, Shahid M. Malik

Question: A 52-year-old Caucasian male with a past medical history of hypertension underwent evaluation for chronic, intermittent abdominal discomfort. He drank an average of 48 ounces of beer daily and had a remote history of intravenous drug use. He … Continue reading →

Posted in News | Comments Off on Hepatitis C and Numerous Disappearing Hepatic Nodules: No-dule C It, No-dule Don’t

Probiotic Gut Bacteria Enhance Cancer Immunotherapy in a Mouse Model of Melanoma

Posted on May 27, 2016 by Neelendu Dey, Matthew A. Ciorba

Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium Promotes Antitumor Immunity and Facilitates Anti-PD-L1 Efficacy. Science 2015;350:1084–1089. Continue reading →

Posted in News | Comments Off on Probiotic Gut Bacteria Enhance Cancer Immunotherapy in a Mouse Model of Melanoma

Probiotic Gut Bacteria Enhance Cancer Immunotherapy in a Mouse Model of Melanoma

Posted on May 27, 2016 by Neelendu Dey, Matthew A. Ciorba

Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium Promotes Antitumor Immunity and Facilitates Anti-PD-L1 Efficacy. Science 2015;350:1084–1089. Continue reading →

Posted in News | Comments Off on Probiotic Gut Bacteria Enhance Cancer Immunotherapy in a Mouse Model of Melanoma

Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections

Posted on May 27, 2016 by Edward J. Gane, Christian Schwabe, Robert H. Hyland, Yin Yang, Evguenia Svarovskaia, Luisa M. Stamm, Diana M. Brainard, John G. McHutchison, Catherine A. Stedman

We performed a phase 2 trial of the efficacy and safety of 4, 6, and 8 weeks of sofosbuvir, given in combination with the NS5A inhibitor velpatasvir and the NS3/4A protease inhibitor GS-9857, in patients with hepatitis C virus (HCV) infection. Continue reading →

Posted in News | Comments Off on Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections

Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-naïve or Previously Treated Patients with HCV Genotype 1 or 3 Infections

Posted on May 27, 2016 by Edward J. Gane, Christian Schwabe, Robert H. Hyland, Yin Yang, Evguenia Svarovskaia, Luisa M. Stamm, Diana M. Brainard, John G. McHutchison, Catherine A. Stedman

We performed a phase 2 trial of the efficacy and safety of 4, 6, and 8 weeks of sofosbuvir, given in combination with the NS5A inhibitor velpatasvir and the NS3/4A protease inhibitor GS-9857, in patients with hepatitis C virus (HCV) infection. Continue reading →

Posted in News | Comments Off on Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-naïve or Previously Treated Patients with HCV Genotype 1 or 3 Infections

Are Facultative Reserve ISCs the Cellular Origin of Familial Small Intestinal Neuroendocrine Tumors?

Posted on May 27, 2016 by Peter J. Dempsey

Serotonin-producing neuroendocrine tumors of the small intestine (SI-NETs; or mid-gut carcinoids) are well-differentiated, slow-growing tumors. Although SI-NETs are relatively uncommon, they represent the most frequent tumor of the distal small intesti… Continue reading →

Posted in News | Comments Off on Are Facultative Reserve ISCs the Cellular Origin of Familial Small Intestinal Neuroendocrine Tumors?

Are Facultative Reserve ISCs the Cellular Origin of Familial Small Intestinal Neuroendocrine Tumors?

Posted on May 27, 2016 by Peter J. Dempsey

Serotonin-producing neuroendocrine tumors of the small intestine (SI-NETs; or mid-gut carcinoids) are well-differentiated, slow-growing tumors. Although SI-NETs are relatively uncommon, they represent the most frequent tumor of the distal small intesti… Continue reading →

Posted in News | Comments Off on Are Facultative Reserve ISCs the Cellular Origin of Familial Small Intestinal Neuroendocrine Tumors?

Mouse Label-Retaining Cells Are Molecularly and Functionally Distinct From Reserve Intestinal Stem Cells

Posted on May 27, 2016 by Ning Li, Angela Nakauka-Ddamba, John Tobias, Shane T. Jensen, Christopher J. Lengner

Intestinal homeostasis and regeneration after injury are controlled by 2 different types of cells: slow cycling, injury-resistant reserve intestinal stem cells (ISCs) and actively proliferative ISCs. Putative reserve ISCs have been identified using a v… Continue reading →

Posted in News | Comments Off on Mouse Label-Retaining Cells Are Molecularly and Functionally Distinct From Reserve Intestinal Stem Cells

Mouse Label-Retaining Cells Are Molecularly and Functionally Distinct From Reserve Intestinal Stem Cells

Posted on May 27, 2016 by Ning Li, Angela Nakauka-Ddamba, John Tobias, Shane T. Jensen, Christopher J. Lengner

Intestinal homeostasis and regeneration after injury are controlled by 2 different types of cells: slow cycling, injury-resistant reserve intestinal stem cells (ISCs) and actively proliferative ISCs. Putative reserve ISCs have been identified using a v… Continue reading →

Posted in News | Comments Off on Mouse Label-Retaining Cells Are Molecularly and Functionally Distinct From Reserve Intestinal Stem Cells